Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity.

Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS.

Nature. 2017 Mar 2;543(7643):122-125. doi: 10.1038/nature21356. Epub 2017 Feb 8.

2.

A 22-Year Old Woman with Right Eyelid Swelling.

van Vugt VA, Kesari A, Muller KA, Carter B, Vandenberg SR, Kesari S.

Brain Pathol. 2016 May;26(3):425-6. doi: 10.1111/bpa.12381. No abstract available.

PMID:
27111386
3.

Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.

Jones KA, Gilder AS, Lam MS, Du N, Banki MA, Merati A, Pizzo DP, VandenBerg SR, Gonias SL.

Neuro Oncol. 2016 May;18(5):667-78. doi: 10.1093/neuonc/nov243. Epub 2015 Sep 29.

4.

Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI.

Barajas RF Jr, Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, Cha S.

Clin Radiol. 2015 Oct;70(10):1087-95. doi: 10.1016/j.crad.2015.03.006. Epub 2015 Jul 29.

PMID:
26231469
5.

Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression.

Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha DS, Merzon D, Ramakrishnan V, Zhu S, Zhu K, Matsui H, Harismendy O, Hua W, Mao Y, Kwon CH, Saya H, Nakano I, Pizzo DP, VandenBerg SR, Chen CC.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4055-64. doi: 10.1073/pnas.1501967112. Epub 2015 Jul 9.

6.

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J.

N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.

7.

A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB.

Cancer Res. 2015 Jan 15;75(2):394-404. doi: 10.1158/0008-5472.CAN-14-2004. Epub 2014 Nov 28.

8.

Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.

Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL.

Oncogene. 2015 Jul 30;34(31):4078-88. doi: 10.1038/onc.2014.336. Epub 2014 Oct 27.

9.

Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).

Farid N, Almeida-Freitas DB, White NS, McDonald CR, Kuperman JM, Almutairi AA, Muller KA, VandenBerg SR, Kesari S, Dale AM.

J Neurooncol. 2014 Dec;120(3):539-46. doi: 10.1007/s11060-014-1583-2. Epub 2014 Aug 19.

10.

72 year old female with leg weakness.

Mahta A, Borys E, Vandenberg SR, Carter B, Kesari S.

Brain Pathol. 2014 Mar;24(2):195-6. No abstract available.

PMID:
25121191
11.

Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.

Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL.

J Pediatr Hematol Oncol. 2014 Aug;36(6):451-7. doi: 10.1097/MPH.0000000000000047.

12.

Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling SC, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu XD, Bennett CF, Cleveland DW, Ravits J.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4530-9. doi: 10.1073/pnas.1318835110. Epub 2013 Oct 29.

13.

Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM.

Farid N, Almeida-Freitas DB, White NS, McDonald CR, Muller KA, Vandenberg SR, Kesari S, Dale AM.

Front Oncol. 2013 Sep 30;3:258. doi: 10.3389/fonc.2013.00258. eCollection 2013.

14.

78 year old male with dysphagia and dysarthria.

Mahta A, Du Z, Borys E, Carter B, Vandenberg SR, Kesari S.

Brain Pathol. 2013 Nov;23(6):705-6. doi: 10.1111/bpa.12093. No abstract available.

PMID:
24118489
15.

PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes.

Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, Ellies LG, Lowy AM, Blair SL, Vandenberg SR, Datnow B, Wang HY, Cheresh DA, Varner J.

Proc Natl Acad Sci U S A. 2013 May 28;110(22):9042-7. doi: 10.1073/pnas.1219603110. Epub 2013 May 13.

16.

Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors.

Staudt ND, Jo M, Hu J, Bristow JM, Pizzo DP, Gaultier A, VandenBerg SR, Gonias SL.

Cancer Res. 2013 Jul 1;73(13):3902-12. doi: 10.1158/0008-5472.CAN-12-4233. Epub 2013 Apr 30.

17.

A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma.

Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB.

PLoS Genet. 2013;9(2):e1003253. doi: 10.1371/journal.pgen.1003253. Epub 2013 Feb 14.

18.

Role of connexins in metastatic breast cancer and melanoma brain colonization.

Stoletov K, Strnadel J, Zardouzian E, Momiyama M, Park FD, Kelber JA, Pizzo DP, Hoffman R, VandenBerg SR, Klemke RL.

J Cell Sci. 2013 Feb 15;126(Pt 4):904-13. doi: 10.1242/jcs.112748. Epub 2013 Jan 15.

19.

Expression of miR-124 inhibits growth of medulloblastoma cells.

Silber J, Hashizume R, Felix T, Hariono S, Yu M, Berger MS, Huse JT, VandenBerg SR, James CD, Hodgson JG, Gupta N.

Neuro Oncol. 2013 Jan;15(1):83-90. doi: 10.1093/neuonc/nos281. Epub 2012 Nov 21.

20.

Recurrent pediatric central nervous system low-grade gliomas: the role of surveillance neuroimaging in asymptomatic children.

Udaka YT, Yeh-Nayre LA, Amene CS, VandenBerg SR, Levy ML, Crawford JR.

J Neurosurg Pediatr. 2013 Feb;11(2):119-26. doi: 10.3171/2012.10.PEDS12307. Epub 2012 Nov 16.

PMID:
23157391
21.

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9. doi: 10.1073/pnas.1211962109. Epub 2012 Aug 13.

22.

Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.

Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15984-9. doi: 10.1073/pnas.1113416108. Epub 2011 Sep 6.

23.

MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.

Khayal IS, Vandenberg SR, Smith KJ, Cloyd CP, Chang SM, Cha S, Nelson SJ, McKnight TR.

Neuro Oncol. 2011 Nov;13(11):1192-201. doi: 10.1093/neuonc/nor122. Epub 2011 Aug 24.

24.

DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C, Haas-Kogan DA, McBride S, Marsit CJ, Christensen BC, Nelson HH, Stokoe D, Wiemels JL, Chang SM, Prados MD, Tihan T, Vandenberg SR, Kelsey KT, Berger MS, Wiencke JK.

Neuro Oncol. 2011 Mar;13(3):280-9. doi: 10.1093/neuonc/noq190.

25.

Non-stem cell origin for oligodendroglioma.

Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Nishiyama A, Stallcup WB, Berger MS, Bergers G, McKnight TR, Goldman SA, Weiss WA.

Cancer Cell. 2010 Dec 14;18(6):669-82. doi: 10.1016/j.ccr.2010.10.033.

26.

Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ.

Neuro Oncol. 2010 Nov;12(11):1152-61. doi: 10.1093/neuonc/noq075. Epub 2010 Jul 20.

27.

Pleiotropic role for MYCN in medulloblastoma.

Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L.

Genes Dev. 2010 May 15;24(10):1059-72. doi: 10.1101/gad.1907510.

28.

Gene expression profiles help identify the tissue of origin for metastatic brain cancers.

Wu AH, Drees JC, Wang H, VandenBerg SR, Lal A, Henner WD, Pillai R.

Diagn Pathol. 2010 Apr 26;5:26. doi: 10.1186/1746-1596-5-26.

29.

A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS.

Cancer Cell. 2010 Apr 13;17(4):362-75. doi: 10.1016/j.ccr.2009.12.049.

30.

Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.

Hashizume R, Gupta N, Berger MS, Banerjee A, Prados MD, Ayers-Ringler J, James CD, VandenBerg SR.

Neuro Oncol. 2010 Apr;12(4):366-76. doi: 10.1093/neuonc/nop033. Epub 2010 Jan 11.

31.

Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors.

Park I, Larson PE, Zierhut ML, Hu S, Bok R, Ozawa T, Kurhanewicz J, Vigneron DB, Vandenberg SR, James CD, Nelson SJ.

Neuro Oncol. 2010 Feb;12(2):133-44. doi: 10.1093/neuonc/nop043. Epub 2010 Jan 25.

32.

Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging.

Barajas RF Jr, Hodgson JG, Chang JS, Vandenberg SR, Yeh RF, Parsa AT, McDermott MW, Berger MS, Dillon WP, Cha S.

Radiology. 2010 Feb;254(2):564-76. doi: 10.1148/radiol.09090663.

33.

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD.

Cancer Res. 2010 Jan 15;70(2):512-9. doi: 10.1158/0008-5472.CAN-09-1851. Epub 2010 Jan 12.

34.

Post-radiation reactive changes in a single vertebral body mimicking metastatic pineoblastoma.

Tate MC, Banerjee A, Vandenberg SR, Tihan T, Chi JH, Ames CP, Parsa AT.

J Neurosurg Pediatr. 2009 Nov;4(5):479-83. doi: 10.3171/2009.6.PEDS09266.

PMID:
19877784
35.

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.

McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2010 Mar;97(1):33-40. doi: 10.1007/s11060-009-0004-4. Epub 2009 Aug 25.

36.

Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, Spellman PT, Vandenberg SR, Berger MS, James CD.

Neuro Oncol. 2009 Oct;11(5):477-87. doi: 10.1215/15228517-2008-113. Epub 2009 Jan 12.

37.

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD.

Cancer Res. 2008 Dec 15;68(24):10034-9. doi: 10.1158/0008-5472.CAN-08-1687.

38.

The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A.

Neoplasia. 2008 Nov;10(11):1204-12.

39.

miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG.

BMC Med. 2008 Jun 24;6:14. doi: 10.1186/1741-7015-6-14.

40.

The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology.

Scheithauer BW, Fuller GN, VandenBerg SR.

Brain Pathol. 2008 Jul;18(3):307-16. doi: 10.1111/j.1750-3639.2008.00179.x. Erratum in: Brain Pathol. 2008 Oct;18(4):640.

PMID:
18532929
41.

Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective.

Krauze MT, Vandenberg SR, Yamashita Y, Saito R, Forsayeth J, Noble C, Park J, Bankiewicz KS.

Exp Neurol. 2008 Apr;210(2):638-44. doi: 10.1016/j.expneurol.2007.12.015. Epub 2007 Dec 27.

42.

An orthotopic skull base model of malignant meningioma.

Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, VandenBerg SR, Lal A.

Brain Pathol. 2008 Apr;18(2):172-9. Epub 2007 Dec 17.

PMID:
18093250
43.

Molecular signatures define two main classes of meningiomas.

Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, Lal A.

Mol Cancer. 2007 Oct 15;6:64.

44.

In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.

Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA.

Neuro Oncol. 2007 Apr;9(2):82-8. Epub 2007 Mar 8.

45.

Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.

Yoo H, Baia GS, Smith JS, McDermott MW, Bollen AW, Vandenberg SR, Lamborn KR, Lal A.

Clin Cancer Res. 2007 Jan 1;13(1):68-75.

47.

A genetic strategy to overcome the senescence of primary meningioma cell cultures.

Baia GS, Slocum AL, Hyer JD, Misra A, Sehati N, VandenBerg SR, Feuerstein BG, Deen DF, McDermott MW, Lal A.

J Neurooncol. 2006 Jun;78(2):113-21. Epub 2006 Mar 23.

PMID:
16554968
48.

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.

Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-Kogan DA.

Mol Cancer Ther. 2005 Dec;4(12):1952-61.

49.

Mitochondrial DNA depletion analysis by pseudogene ratioing.

Swerdlow RH, Redpath GT, Binder DR, Davis JN 2nd, VandenBerg SR.

J Neurosci Methods. 2006 Jan 30;150(2):265-71. Epub 2005 Aug 22.

PMID:
16118020
50.

Indicators of hippocampal neurogenesis are altered by 56Fe-particle irradiation in a dose-dependent manner.

Rola R, Otsuka S, Obenaus A, Nelson GA, Limoli CL, VandenBerg SR, Fike JR.

Radiat Res. 2004 Oct;162(4):442-6.

PMID:
15447038

Supplemental Content

Loading ...
Support Center